Director/PDMR and PCA Shareholding

RNS Number : 0989N
Advanced Medical Solutions Grp PLC
03 May 2018


3 May 2018

  Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

  Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 30 April 2018 that Simon Coates, who is a PDMR, following the successful achievement of certain performance criteria, had on 30 April 2018 exercised and sold 28,193 options from the Long Term Incentive Plan (LTIP). His beneficial ownership remains unchanged.

 

The Company further announces that it was notified on 30 April 2018 that Jeff Willis, who is a PDMR, following the successful achievement of certain performance criteria, had on 30 April 2018 exercised and sold 40,350 options from the Long Term Incentive Plan (LTIP). His beneficial ownership remains unchanged.

 

Long Term Incentive Plan (LTIP)

 

 

PDMR

No. of LTIPs prior to exercise

LTIPs exercised

Ordinary Shares sold

Ordinary shares retained

LTIPs after exercise

Simon Coates

PDMR

84,275

28,193

28,193

Nil

56,082

Jeff Willis

PDMR

156,678

40,350

40,350

Nil

116,328

 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

 

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Simon Coates

2.

Reason for the notification

a)

Position/status: PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

· Exercise of 28,193 shares from the Long Term Incentive Plan

· Sale of 28,193 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£3.0677

28,193

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 28,193

Aggregated price: £3.0677

e)

Date of the transaction: 30/04/2018

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Jeff Willis

2.

Reason for the notification

a)

Position/status: PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

· Exercise of 40,350 shares from the Long Term Incentive Plan

· Sale of 40,350 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£3.0677

40,350

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 40,350

Aggregated price: £3.0677

e)

Date of the transaction: 30/04/2018

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

End –

 

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Philippa Gardner

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange

END

DSHLLFFDERIVIIT